Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

Thumbnail
Name:
Publisher version
Author
Lara, Beatriz
Publication date
2022-07
Subject
Respiratory medicine
Communicable diseases

Metadata
Show full item record
Abstract
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Citation
Lancet . 2022 Jul 30;400(10349):359-368
Type
Article
Handle
http://hdl.handle.net/20.500.14200/1922
Additional Links
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333998/
DOI
10.1016/S0140-6736(22)01109-6
PMID
35908569
Journal
The Lancet
Publisher
Elsevier
Collections